Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: results from the ATAC trial

被引：0
|
作者：
Duffy, SR
Distler, W
机构：
[1] St James Univ Hosp, Leeds, W Yorkshire, England
[2] Univ Klinikum Carl Gustav Carus, Dresden, Germany
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [31] The anastrozole, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial in post-menopausal women: Regional variations in surgical practice in patients recruited into the trial. The ATAC Trialists' Group.
    Sainsbury, R
    ANNALS OF ONCOLOGY, 2000, 11 : 20 - 20
  • [32] The effect of anastrozole on bone mineral density: updated results from the bone subprotocol of the ATAC trial
    Eastell, R.
    Coleman, R.
    Mansel, R.
    Bianco, A.
    Nagykalnai, T.
    Cuzick, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S109 - S109
  • [33] Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: Updated data from the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial.
    Houghton, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 24S - 24S
  • [34] Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
    Li, Jian-wei
    Liu, Guang-yu
    Ji, Ya-jie
    Yan, Xia
    Pang, Da
    Jiang, Ze-fei
    Chen, De-dian
    Zhang, Bin
    Xu, Bing-he
    Shao, Zhi-ming
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 299 - 307
  • [35] Switching to anastrozole plus goserelin versus continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: Preliminary results from a randomized trial
    Jian-wei, L.
    Guangyu, L.
    Yajie, J.
    Xia, Y.
    Zhimin, S.
    Da, P.
    Zefei, J.
    Dedian, C.
    Bin, Z.
    Binghe, X.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S315 - S315
  • [36] Fewer gynaecological adverse events (AEs), gynaecological interventions, endometrial changes and abnormalities with anastrozole than with tamoxifen: findings from the ATAC ('Arimidex', Tarmoxifen, Alone or in Combination) trial
    Distler, W.
    BREAST, 2007, 16 : S45 - S46
  • [37] Effect of stopping anastrozole on bone mineral density: Seven-year results from the ATAC trial
    Eastell, R.
    Adams, J. E.
    Clack, G.
    Howell, A.
    Hannon, R. A.
    Cuzick, J.
    Mackey, J. R.
    Beckmann, M.
    Coleman, R.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S84 - S84
  • [38] Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial
    Mansel, R.
    Locker, G.
    Fallowfield, L.
    Benedict, A.
    Jones, D.
    BRITISH JOURNAL OF CANCER, 2007, 97 (02) : 152 - 161
  • [39] Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial
    R Mansel
    G Locker
    L Fallowfield
    Á Benedict
    D Jones
    British Journal of Cancer, 2007, 97 : 152 - 161
  • [40] The anastrozole, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial in post-menopausal women: Regional variation in knowledge of hormone receptor status prior to randomisation into the trial. The ATAC Trialists' Group.
    Howell, A
    ANNALS OF ONCOLOGY, 2000, 11 : 20 - 20
12345